✦ LIBER ✦

The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients

✍ Scribed by Marina Karmochkine; Ali Si Mohamed; Christophe Piketty; Christine Ginsburg; Gilles Raguin; Véronique Schneider-Fauveau; Laurent Gutmann; Michel D. Kazatchkine; Laurent Belec

Book ID: 114144103
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 120 KB
Volume: 47
Category: Article
ISSN: 0166-3542
DOI: 10.1016/s0166-3542(00)00110-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The HIV-1 protease resistance mutation I

The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts

✍ P. Sista; B. Wasikowski; P. Lecocq; T. Pattery; L. Bacheler 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 205 KB

Drug resistance mutations and newly reco

Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: Prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients

✍ Carlo Torti; Eugenia Quiros-Roldan; Laura Monno; Andrea Patroni; Annalisa Saraci 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

## Abstract This study aimed at identifying HIV‐1 protease amino acid changes associated with protease inhibitor (PI) exposure and susceptibility. New amino acid substitutions were correlated with the number of experienced PIs, reaching statistical significance only for those at positions 3, 44, an

Efficacy and tolerability of a double bo

Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors

✍ P Chetchotisakd; S Anunnatsiri; P Mootsikapun; S Kiertiburanakul; T Anekthananon 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

Long-term follow-up of 11 protease inhib

Long-term follow-up of 11 protease inhibitor (PI)-naïve and PI-treated HIV-infected patients harbouring virus with insertions in the HIV-1 protease gene

✍ C Amiel; C Charpentier; N Désiré; P Bonnard; M-G Lebrette; L Weiss; G Pialoux; V 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 292 KB

P1235 BASELINE/EARLY PRESENCE OF KNOWN A

P1235 BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS

✍ Cento, V.; Di Maio, V.C.; Di Paolo, D.; Micheli, V.; Tontodonati, M.; De Leonard 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Efficacy and safety of once daily elvite

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

✍ Jean-Michel Molina; Anthony LaMarca; Jaime Andrade-Villanueva; Bonaventura Clote 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 209 KB